Heilongjiang ZBD Pharmaceutical Co Ltd
Heilongjiang ZBD Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of Chinese medicines in China. It offers cardiovascular and cerebrovascular, respiratory system, orthopedics, tumors, digestive system, anti-infection, mental nerve, genitourinary, and other disease fields. The company was founded in 1996 and is based in Hulin, China.
Heilongjiang ZBD Pharmaceutical Co Ltd (603567) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.039x
Based on the latest financial reports, Heilongjiang ZBD Pharmaceutical Co Ltd (603567) has a cash flow conversion efficiency ratio of 0.039x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥283.54 Million) by net assets (CN¥7.29 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Heilongjiang ZBD Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Heilongjiang ZBD Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Heilongjiang ZBD Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Heilongjiang ZBD Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CellaVision AB (publ)
PINK:CLVSF
|
0.058x |
|
Enjoyor
SHE:300020
|
0.013x |
|
Dingli Communications Corp Ltd
SHE:300050
|
-0.011x |
|
MEC Company Ltd.
PINK:MECGF
|
N/A |
|
Fine Organic Industries Limited
NSE:FINEORG
|
0.066x |
|
Myriad Genetics Inc
NASDAQ:MYGN
|
0.029x |
|
Jiangsu Hanvo Safety Product Co. Ltd.
SHE:300952
|
0.027x |
|
Stratasys Ltd
NASDAQ:SSYS
|
0.006x |
Annual Cash Flow Conversion Efficiency for Heilongjiang ZBD Pharmaceutical Co Ltd (2011–2024)
The table below shows the annual cash flow conversion efficiency of Heilongjiang ZBD Pharmaceutical Co Ltd from 2011 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥8.29 Billion | CN¥164.31 Million | 0.020x | +134.80% |
| 2023-12-31 | CN¥8.04 Billion | CN¥-457.90 Million | -0.057x | -23.85% |
| 2022-12-31 | CN¥7.11 Billion | CN¥-326.79 Million | -0.046x | +25.28% |
| 2021-12-31 | CN¥7.05 Billion | CN¥-433.94 Million | -0.062x | -318.25% |
| 2020-12-31 | CN¥5.50 Billion | CN¥155.18 Million | 0.028x | -32.99% |
| 2019-12-31 | CN¥5.25 Billion | CN¥220.92 Million | 0.042x | -42.93% |
| 2018-12-31 | CN¥4.98 Billion | CN¥367.40 Million | 0.074x | -59.57% |
| 2017-12-31 | CN¥4.68 Billion | CN¥853.19 Million | 0.182x | +4862.02% |
| 2016-12-31 | CN¥4.31 Billion | CN¥15.83 Million | 0.004x | +104.52% |
| 2015-12-31 | CN¥3.98 Billion | CN¥-323.90 Million | -0.081x | -145.75% |
| 2014-12-31 | CN¥2.17 Billion | CN¥386.32 Million | 0.178x | +77.83% |
| 2013-12-31 | CN¥1.75 Billion | CN¥174.68 Million | 0.100x | -14.48% |
| 2012-12-31 | CN¥1.32 Billion | CN¥154.25 Million | 0.117x | +3.07% |
| 2011-12-31 | CN¥923.09 Million | CN¥104.71 Million | 0.113x | -- |